WEKO3
アイテム
Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
http://hdl.handle.net/10295/00005838
http://hdl.handle.net/10295/00005838f7066300-55c8-4595-affc-d8a75189129d
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-11-25 | |||||
タイトル | ||||||
タイトル | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
主題 | ||||||
主題Scheme | Other | |||||
主題 | tacrolimus | |||||
主題 | ||||||
主題Scheme | Other | |||||
主題 | everolimus | |||||
主題 | ||||||
主題Scheme | Other | |||||
主題 | CYP3A5 polymorphism | |||||
主題 | ||||||
主題Scheme | Other | |||||
主題 | renal transplantation | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
作成者 |
Kagaya, Hideaki
× Kagaya, Hideaki× Niioka, Takenori× Saito, Mitsuru× Inoue, Takamitsu× Numakura, Kazuyuki× Yamamoto, Ryohei× Akamine, Yumiko× HABUCHI, Tomonori× SATOH, Shigeru× Miura, Masatomo |
|||||
内容記述 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | While tacrolimus and everolimus have common metabolic pathways through CYP3A4/5, tacrolimus is metabolized solely by CYP3A4 in recipients with the CYP3A5*3/*3. The purpose of this study was to evaluate how the area under the blood concentration-time curves (AUC) of tacrolimus could be predicted based on CYP3A5 genotype and the AUC of everolimus in renal transplant patients taking both drugs. The dose-adjusted AUC (AUC/D) of tacrolimus and everolimus were calculated at one month and one year after transplantation. Significant correlations between the AUC/D of tacrolimus and everolimus were found for patients with the CYP3A5*1 allele or CYP3A5*3/*3 at both one month and one year. At both stages, the determination coefficients were higher and the slopes of regression equations were larger for patients with CYP3A5*3/*3 compared to the CYP3A5*1 allele. A good correlation between single doses of tacrolimus and everolimus was found for CYP3A5*3/*3 patients at 1 year after transplantation (r = 0.794, p < 0.001). The variability of the AUC0–24/D of tacrolimus for each CYP3A5 genotype could be predicted based on the AUC0–12/D of everolimus. Clinicians may be able to comprehensively carry out the dose adjustments of tacrolimus and everolimus based on relationship with AUCs of both drugs in each CYP3A5 genotype. | |||||
言語 | en | |||||
出版タイプ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
書誌情報 |
International Journal of Molecular Sciences 巻 19, 号 3, p. 882, 発行日 2018 |
|||||
収録物識別子 | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1422-0067 | |||||
出版者 | ||||||
出版者 | MDPI | |||||
関連情報 | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.3390/ijms19030882 | |||||
権利情報 | ||||||
権利情報 | © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |